Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS1128 in mild to moderate COVID-19
NCT05689203Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QLS-1128 in coronavirus disease 2019 (COVID-19), sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
QLS-1128
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05689203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689203.